Dianthus Therapeutics (NASDAQ:DNTH) Coverage Initiated at Oppenheimer

Oppenheimer initiated coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research note issued to investors on Thursday morning, MarketBeat.com reports. The firm issued an outperform rating and a $48.00 target price on the stock.

DNTH has been the subject of several other research reports. HC Wainwright restated a buy rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Thursday, September 26th. Cantor Fitzgerald began coverage on shares of Dianthus Therapeutics in a research report on Thursday, June 27th. They issued an overweight rating for the company. Lifesci Capital raised Dianthus Therapeutics to a strong-buy rating in a report on Tuesday, June 11th. Robert W. Baird began coverage on Dianthus Therapeutics in a report on Friday, July 26th. They issued an outperform rating and a $58.00 target price for the company. Finally, Wedbush decreased their target price on Dianthus Therapeutics from $38.00 to $36.00 and set an outperform rating for the company in a research report on Friday, August 9th. Nine equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Dianthus Therapeutics has a consensus rating of Buy and an average target price of $45.13.

Dianthus Therapeutics Price Performance

Dianthus Therapeutics stock opened at $28.00 on Thursday. The stock’s fifty day moving average is $27.87 and its two-hundred day moving average is $26.23. The stock has a market cap of $821.77 million, a PE ratio of -4.80 and a beta of 1.85. Dianthus Therapeutics has a 1-year low of $6.58 and a 1-year high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.01). The business had revenue of $1.86 million for the quarter, compared to analysts’ expectations of $0.63 million. Dianthus Therapeutics had a negative return on equity of 21.03% and a negative net margin of 1,376.42%. On average, research analysts expect that Dianthus Therapeutics will post -2.32 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC purchased a new position in shares of Dianthus Therapeutics in the 2nd quarter valued at approximately $112,000. American Century Companies Inc. lifted its holdings in shares of Dianthus Therapeutics by 38.6% during the second quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock worth $788,000 after purchasing an additional 8,473 shares during the period. The Manufacturers Life Insurance Company purchased a new position in Dianthus Therapeutics in the 2nd quarter valued at $236,000. WINTON GROUP Ltd acquired a new position in Dianthus Therapeutics in the 2nd quarter valued at $265,000. Finally, Point72 DIFC Ltd purchased a new position in Dianthus Therapeutics during the 2nd quarter worth $334,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.